Results 191 to 200 of about 12,992 (201)

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use

Pediatric Nephrology, 2018
Jack Wetzels, Kioa Wijnsma
exaly  

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis

Muscle and Nerve, 2019
Maurizio Inghilleri, John Vissing, Josef Bednarik   +2 more
exaly  

Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn

Immunobiology, 2015
Vedran Štefanovic, Ole-Lars Brekke, Randi Fykse Hallstensen   +2 more
exaly  

Eculizumab in pregnancy: a narrative overview

Journal of Nephrology, 2018
Laura Sarno, Giuseppe Maruotti, Domenico Russo   +2 more
exaly  

Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders

Clinical and Experimental Immunology, 2017
K Kentouche, H Fehrenbach, R Weimer
exaly  

ECULIZUMAB

Reactions Weekly, 2014
openaire   +2 more sources

Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome

Kidney International Reports, 2019
Fadi Fakhouri, Franz Schaefer, David Cohen   +2 more
exaly  

Disseminated Gonococcal Infections in Patients Receiving Eculizumab: A Case Series

Clinical Infectious Diseases, 2019
Kyle Bernstein, Robert Kirkcaldy, Winston Abara   +2 more
exaly  

Eculizumab deposits in vessel walls in thrombotic microangiopathy

Kidney International, 2019
Clarissa Cassol, Spero Cataland, Anjali Satoskar   +2 more
exaly  

FDA Report: Eculizumab (Soliris®) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria

Oncologist, 2008
Martin H Cohen
exaly